Insights
What Is SPRAVATO and Who Is It For?
Quick answer
SPRAVATO (esketamine) is a prescription nasal spray, given under healthcare supervision, for certain adults with depression. The FDA label lists treatment-resistant depression, and depressive symptoms in adults with major depressive disorder who have acute suicidal thoughts or behavior, used with an oral antidepressant. Patients are monitored for at least two hours after each session.SPRAVATO (esketamine) is a prescription nasal spray approved by the FDA for certain adults with depression. It is given in a supervised healthcare setting, not taken at home. This page summarizes what the FDA prescribing information says, so you can have an informed conversation with a clinician.
What SPRAVATO Is
According to the FDA prescribing information, SPRAVATO is a nasal spray that contains esketamine, a controlled substance classified as Schedule III. The label describes it as an NMDA receptor antagonist. Each nasal spray device delivers two sprays, and the device is for nasal use only. Treatment is given under the direct supervision of a healthcare provider.
Who It Is Approved For
The label lists two uses in adults:
- Treatment-resistant depression, either on its own or together with an oral antidepressant
- Depressive symptoms in adults with major depressive disorder who have acute suicidal thoughts or behavior, used together with an oral antidepressant
The label also lists limits. It states that the effectiveness of SPRAVATO in preventing suicide or in reducing suicidal thoughts or behavior has not been demonstrated, and that using it does not remove the need for hospitalization when a clinician judges that necessary. It is not approved as an anesthetic, and it is not approved for use in pediatric patients.
Some people should not use it. The label lists contraindications that include aneurysmal vascular disease, arteriovenous malformation, intracerebral hemorrhage and hypersensitivity to esketamine or ketamine. Only a clinician who reviews your history can tell you whether it is appropriate for you.
What a Treatment Session Involves
A session includes both the spray and a period of observation. Before dosing, the clinic assesses your blood pressure. The label calls for a recheck at about 40 minutes after dosing and again as clinically needed. You are monitored for at least two hours at each session, including your breathing, and then assessed to decide whether you are stable enough to leave the healthcare setting.
The label advises avoiding food for at least two hours before a session and avoiding liquids for at least 30 minutes before, because nausea and vomiting can occur. Anyone who needs a nasal corticosteroid or decongestant on a dosing day is advised to use it at least one hour before SPRAVATO.
For treatment-resistant depression, the label describes an induction phase of twice-weekly sessions for four weeks, followed by weekly sessions for weeks five through eight, and then sessions every two weeks or weekly from week nine onward, with the frequency individualized. The label calls for evaluating whether treatment is helping at the end of the induction phase.
Safety Points to Know
SPRAVATO carries a boxed warning, the FDA's strongest type of warning. It covers sedation, dissociation, respiratory depression, the potential for abuse and misuse, and an increased risk of suicidal thoughts and behaviors in pediatric and young adult patients taking antidepressants. Because of these risks, SPRAVATO is available only through a restricted program called the SPRAVATO REMS.
The most commonly observed side effects in treatment-resistant depression, according to the label, include dissociation, dizziness, nausea, sedation, vertigo, reduced sensation, anxiety, lethargy, increased blood pressure, vomiting, feeling drunk and headache. The label also says patients should not drive or operate machinery until the next day after a restful sleep. It states that SPRAVATO may cause fetal harm and that breastfeeding is not recommended.
Talking With a Clinician
SPRAVATO is one option among several for depression that has not responded to other care. If you are curious about it, ask a licensed clinician how it compares with other treatments you have tried, what monitoring would involve, and how it would fit with your current medications. Do not stop or change any medication on your own.
TMS Therapy Centers Colorado offers consultations for TMS, SPRAVATO and ketamine therapy - reach the clinic through this site.
This article is for education only and is not medical advice. Talk with a licensed clinician about your situation.